Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11216766 | 0.94 | GRIN1 (0.50) | GRIN1GRIN2AGRIN2BMEN1KMT2A | |
| SCHEMBL13962905 | 0.92 | GRIN1 (0.49) | GRIN1GRIN2AGRIN2BMEN1KMT2A | |
| SCHEMBL2308362 | 0.88 | GRIN1 (0.51) | GRIN1GRIN2AGRIN2BMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29616133 | 0.86 | GRIN1 (0.50) | GRIN1GRIN2AGRIN2BMEN1KMT2A | |
| SCHEMBL2307237 | 0.81 | GRIN1 (0.39) | GRIN1GRIN2AGRIN2BPOLBOPRM1 | |
| SCHEMBL11057716 | 0.78 | GRIN1 (0.47) | GRIN1GRIN2AGRIN2BMEN1KMT2A | |
| SCHEMBL2308698 | 0.78 | GRIN1 (0.53) | GRIN1GRIN2AGRIN2BMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6818616 | 0.77 | GRIN1 (0.51) | GRIN1GRIN2AGRIN2BMEN1KMT2A | |
| SCHEMBL18794819 | 0.73 | GRIN1 (0.51) | GRIN1GRIN2AGRIN2BMEN1KMT2A | |
| SCHEMBL18822335 | 0.73 | GRIN1 (0.48) | GRIN1GRIN2AGRIN2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | claimed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | claimed |
| US-8815869-B2 | Lactam acetamides as calcium channel blockers | ABBVIE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2173747-B1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2011-12-21 | — | — | EP | disclosed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2011115813-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | US | disclosed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-08-26 | — | — | US | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | GRIN1 124/4885GRIN2A 239/4885GRIN2B 165/4885 |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1D, CACNA1S | GRIN1 67/4885GRIN2A 387/4885GRIN2B 248/4885 |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | AZI2, NIT2, NISCH | GRIN1 508/4885GRIN2A 916/4885GRIN2B 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.